MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

8621	Companies
142891	Keywords
78626	Articles
76348	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 04/16/2025 at 14:05, 4 days 13 hours ago

MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique

Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
BRIEF

published on 04/16/2025 at 14:05, 4 days 13 hours ago

MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
PRESS RELEASE

published on 04/16/2025 at 14:00, 4 days 13 hours ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned

Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy
BRIEF

published on 04/01/2025 at 14:05, 19 days 13 hours ago

MIRA Pharmaceuticals fait progresser l'essai du kétamir-2 pour la douleur neuropathique

Recherche Clinique Croissance Pharmaceutique Douleur Neuropathique Extension Du Pipeline Essai Du Kétamir-2
BRIEF

published on 04/01/2025 at 14:05, 19 days 13 hours ago

MIRA Pharmaceuticals Advances Ketamir-2 Trial for Neuropathic Pain

Clinical Research Pharmaceutical Growth Neuropathic Pain Pipeline Expansion Ketamir-2 Trial
PRESS RELEASE

published on 04/01/2025 at 14:00, 19 days 13 hours ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals announces Phase 1 trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, with promising preclinical data. Expansion into topical formulation and strategic acquisition plans to advance pipeline

Clinical Development Phase 1 Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 03/24/2025 at 12:35, 27 days 14 hours ago

MIRA Pharmaceuticals to Acquire SKNY, Bolstering Drug Development

Smoking Cessation MIRA Pharmaceuticals Pharmaceutical Acquisition Weight Loss Drugs SKNY-1 Development
BRIEF

published on 03/24/2025 at 12:35, 27 days 14 hours ago

MIRA Pharmaceuticals va acquérir SKNY, renforçant ainsi le développement de médicaments

MIRA Pharmaceuticals Acquisition Pharmaceutique Arrêt Du Tabac Médicaments Pour La Perte De Poids Développement Du SKNY-1
PRESS RELEASE

published on 03/24/2025 at 12:30, 27 days 14 hours ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
MIRA acquires SKNY Pharmaceuticals, enhancing pipeline with next-gen oral therapeutic for obesity and smoking. Strategic move to address leading causes of preventable death

Acquisition Smoking Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals
BRIEF

published on 03/13/2025 at 13:05, 1 month 7 days ago

MIRA Pharmaceuticals Enhances Ketamir-2 with Topical Pain Treatment

Pain Management Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain

1 2 ... 6

Accesswire

Published on 04/18/2025 at 23:35, 2 days 3 hours ago

urban-gro, Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Published on 04/18/2025 at 01:20, 3 days 1 hour ago

Aston Bay Files Technical Report for Storm Copper Project Initial Mineral Resource Estimate
Published on 04/18/2025 at 00:42, 3 days 2 hours ago

Regency Silver Announces New CEO
Published on 04/18/2025 at 00:00, 3 days 3 hours ago

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Published on 04/17/2025 at 23:50, 3 days 3 hours ago

Fourth Quarter and Year-End 2024 Results

View all ACCESSWIRE

EQS Group

Published on 04/18/2025 at 18:00, 2 days 9 hours ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.03.25.
Published on 04/18/2025 at 18:00, 2 days 9 hours ago

E-PANGO: Résultats annuels 2024
Published on 04/18/2025 at 17:54, 2 days 9 hours ago

VALBIOTIS SA: Compte-rendu de l’Assemblée générale mixte du 18 avril 2025
Published on 04/18/2025 at 17:52, 2 days 9 hours ago

Market entry in France – Cicor acquires significant business activities of Éolane
Published on 04/18/2025 at 17:45, 2 days 9 hours ago

Linedata Services: Déclaration des transactions sur actions propres opération du 16 avril 2025

Les Echos

Published on 04/18/2025 at 17:45, 2 days 9 hours ago

Saint-Gobain once again featured on CDP’s “Climate A List”
Published on 04/18/2025 at 17:45, 2 days 9 hours ago

Saint-Gobain figure une nouvelle fois sur la « Climate A List » établie par le CDP
Published on 04/18/2025 at 11:16, 2 days 15 hours ago

Déclaration hebdomadaire d'opérations effectuées du 14 au 17 avril 2025
Published on 04/18/2025 at 11:16, 2 days 15 hours ago

Disclosure of transactions in own shares from April 14 to April 17, 2025
Published on 04/18/2025 at 07:00, 2 days 20 hours ago

Uitnodiging voor de Jaarvergadering en Buitengewone Algemene Vergadering van aandeelhouders

View all LES ECHOS COMFI WIRE